Legal & General Group Plc lowered its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 1.7% during the first quarter, Holdings Channel reports. The firm owned 8,593 shares of the biopharmaceutical company’s stock after selling 150 shares during the period. Legal & General Group Plc’s holdings in Xencor were worth $204,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Norges Bank bought a new position in shares of Xencor during the fourth quarter worth $15,601,000. Creative Planning increased its position in shares of Xencor by 2.7% in the first quarter. Creative Planning now owns 38,400 shares of the biopharmaceutical company’s stock worth $919,000 after buying an additional 1,000 shares during the period. Adams Diversified Equity Fund Inc. increased its position in shares of Xencor by 2.9% in the first quarter. Adams Diversified Equity Fund Inc. now owns 28,100 shares of the biopharmaceutical company’s stock worth $672,000 after buying an additional 800 shares during the period. Vident Investment Advisory LLC increased its position in shares of Xencor by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 34,624 shares of the biopharmaceutical company’s stock worth $828,000 after buying an additional 5,768 shares during the period. Finally, Teachers Advisors LLC increased its position in shares of Xencor by 2.0% in the fourth quarter. Teachers Advisors LLC now owns 319,914 shares of the biopharmaceutical company’s stock worth $8,420,000 after buying an additional 6,392 shares during the period. Institutional investors own 74.12% of the company’s stock.

Shares of Xencor, Inc. (XNCR) traded up 0.47% on Friday, reaching $21.38. 168,022 shares of the company were exchanged. The firm’s 50 day moving average price is $22.61 and its 200 day moving average price is $23.05. The stock’s market capitalization is $1.00 billion. Xencor, Inc. has a 52 week low of $18.45 and a 52 week high of $29.38.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.10. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. The business had revenue of $13.34 million during the quarter, compared to analysts’ expectations of $8.15 million. Equities research analysts anticipate that Xencor, Inc. will post ($1.17) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/12/xencor-inc-nasdaqxncr-shares-sold-by-legal-general-group-plc.html.

XNCR has been the topic of a number of research analyst reports. Wedbush restated an “outperform” rating and set a $29.00 price objective on shares of Xencor in a research report on Tuesday, June 6th. Zacks Investment Research downgraded shares of Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Finally, Canaccord Genuity restated a “buy” rating and set a $36.00 price objective on shares of Xencor in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $29.33.

In other Xencor news, major shareholder John S. Stafford III acquired 6,000 shares of the firm’s stock in a transaction on Wednesday, June 28th. The stock was acquired at an average cost of $19.94 per share, for a total transaction of $119,640.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder John S. Stafford III acquired 1,500 shares of the firm’s stock in a transaction on Friday, June 16th. The shares were acquired at an average price of $19.67 per share, with a total value of $29,505.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 34,766 shares of company stock valued at $739,408. Company insiders own 4.03% of the company’s stock.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.